Drugs / V934-EP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00753415 | Aug 2008 → Apr 2011 | breast cancer, colon carcinoma, melanoma, non-small cell lung carcinoma +3 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V934-EP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00753415 ↗ |
| Modality | Vaccine | “Two vaccines will be administered: V934-electroporation (EP) either low dose (LD) or high dose (HD), and V935 either LD or HD.” NCT00753415 ↗ |